We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
News

Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference

Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
News

Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm International SA (Debiopharm) has announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.

“Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies” said Dr Nigel McCracken, Vice President, Translational Medicine.

Dr McCracken continued, “Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers”.

Advertisement